opicinumab
mAbexperimental
Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as "Anti-Lingo-1". — Wikipedia
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01052506)
Timeline
Indications
Mechanism of action
- Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1INHIBITOR
LINGO1 inhibitor
Antagonism of LINGO-1 exhibits neuroprotective effects in animal models
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOpicinumab ↗
- ChEMBLCHEMBL3544922 ↗
- ChEMBLCHEMBL2109507 ↗
Also known as
- anti-lingo
- biib033
- biib-033
- opicinumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03222973 | Phase 2 | Nov 14, 2017 | Biogen |
| NCT02833142 | Phase 1 | Jul 1, 2016 | Biogen |
| NCT02641041 | Phase 1 | Feb 1, 2016 | Biogen |
| NCT01864148 | Phase 2 | Aug 1, 2013 | Biogen |
| NCT01721161 | Phase 2 | Dec 1, 2012 | Biogen |
| NCT01244139 | Phase 1 | Oct 1, 2010 | Biogen |
| NCT01052506 | Phase 1 | Jan 1, 2010 | Biogen |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 7 | 7 | 2 | 2010 |
1 organizations
Page 1 / 1